Código QR (código de barras bidimensional)

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report

Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symp...

ver descrição completa

Na minha lista:
Principais autores: Cristina M. Merkhofer, MD, MHS, Christina S. Baik, MD, MPH
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021-06-01
coleção:JTO Clinical and Research Reports
Assuntos:
Pemetrexed
EGFR mutation
Non–small cell lung cancer
Leptomeningeal disease
Case report
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2666364321000369
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados